Home
HelpTest Code BADX BCR/ABL1, Qualitative, Diagnostic Assay, Varies
Reporting Name
BCR/ABL1, RNA-Qual, DiagnosticUseful For
Diagnostic workup of patients with a high probability of BCR::ABL1-positive hematopoietic neoplasms, predominantly chronic myeloid leukemia and acute lymphoblastic leukemia
Testing Algorithm
For more information see:
-Myeloproliferative Neoplasm: A Diagnostic Approach to Bone Marrow Evaluation
-Myeloproliferative Neoplasm: A Diagnostic Approach to Peripheral Blood Evaluation
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Specimen Type
VariesOrdering Guidance
This test is only qualitative and should not be used for routine monitoring (ie, quantitative messenger RNA [mRNA] level).
Monitoring of most patients with chronic myeloid leukemia should be performed using BCRAB / BCR/ABL1, p210, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Chronic Myelogenous Leukemia (CML), Varies.
Monitoring of patients known to carry a p190 fusion should be performed using BA190 / BCR/ABL1, p190, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Assay, Varies.
Additional testing options are available. For ordering guidance see BCR/ABL1 Ordering Guide for Blood and Bone Marrow
Shipping Instructions
1. Refrigerate specimens must arrive within 5 days of collection, and ambient specimens must arrive with 3 days of collection.
2. Collect and package specimens as close to shipping time as possible.
Necessary Information
Pertinent clinical history including if the patient has a diagnosis of chronic myelogenous leukemia or other BCR::ABL1-positive neoplasm is required.
Specimen Required
Submit only 1 of the following specimens:
Specimen Type: Whole blood
Container/Tube:
Preferred: Lavender top (EDTA)
Acceptable: Yellow top (ACD)
Specimen Volume: 10 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. Do not aliquot.
3. Label specimen as blood.
Specimen Type: Bone marrow
Container/Tube:
Preferred: Lavender top (EDTA)
Acceptable: Yellow top (ACD)
Specimen Volume: 4 mL
Collection Instructions:
1. Invert several times to mix bone marrow.
2. Send bone marrow specimen in original tube. Do not aliquot.
3. Label specimen as bone marrow.
Specimen Minimum Volume
Peripheral blood: 8 mL; Bone marrow: 2 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Varies | Refrigerated (preferred) | 5 days | PURPLE OR PINK TOP/EDTA |
| Ambient | 72 hours | PURPLE OR PINK TOP/EDTA |
Special Instructions
Reference Values
A qualitative result is provided that indicates the presence or absence of BCR::ABL1 messenger RNA. When positive, the fusion variant is also reported.
Day(s) Performed
Monday through Saturday
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
81206
81207
81208
81479 (if appropriate for government payers)
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| BADX | BCR/ABL1, RNA-Qual, Diagnostic | 55135-8 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 39466 | Diagnostic BCR/ABL1 Result | No LOINC Needed |
| MP001 | Specimen Type | 31208-2 |
| 19783 | Interpretation | 69047-9 |
Interpretation
An interpretive report will be provided.
When positive, the test identifies the specific messenger RNA fusion variant present to guide selection of an appropriate monitoring assay.
Monitoring is available for common p210 or p190 fusion variant detected.
-Common fusion variants detected: e13-a2 or e14-a2 (p210), e1-a2 (p190), and e6-a2 (p205*)
-Rare fusion variants detected: e13-a3 (p210), e14-a3 (p210), e1-a3 (p190), e19-a2 (p230)
-Potential rare fusions detected: e12-a3, e19-a3
*This is formerly observed as the e6-a2 (p185) fusion form.
Clinical Reference
1. Burmeister T, Reinhardt R. A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts. Leuk Res 2008;32(4):579-585
2. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996;88(7):2375-2384
3. Melo JV. BCR-ABL gene variants. Baillieres Clin Haematol. 1997;10(2):203-222
4. Tefferi A. The classic myeloproliferative neoplasms: Chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, and primary myelofibrosis. In: Valle DL, Antonarakis S, Ballabio A, Beaudet AL, Mitchell GA, eds. The Online Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill; 2019, Accessed January 5, 2024. Available at https://ommbid.mhmedical.com/content.aspx?sectionid=225078035&bookid=2709
Report Available
5 to 10 daysMethod Name
Reverse Transcription Polymerase Chain Reaction (RT-PCR) Multiplex PCR
Forms
1. Hematopathology Patient Information (T676)
2. If not ordering electronically, complete, print, and send a Hematopathology/Cytogenetics Test Request (T726) with the specimen.